Aspira Appoints Three New Directors, Executes $2.0 Million Equity Purchase Agreement
Aspira Women's Health (NASDAQ:AWH) has announced significant board changes with the appointment of three new directors: Dr. Jeffrey Cohen, Cindy Hundorfean, and Jack Fraser. Dr. Cohen brings over 40 years of urological expertise and robot-assisted surgery experience, while Hundorfean contributes senior healthcare leadership experience as a partner at The CEO Advisory Network. Fraser adds financial expertise from his 25-year tenure at Seamark Capital.
The company also executed a $2.0 million equity purchase agreement with Triton Funds LP. The proceeds will support ongoing commercial activities, working capital, and general corporate purposes. A key focus remains on driving sales growth and completing their current endometriosis clinical study for the ENDOInform™ blood test.
Dr. Celeste Fralick will be departing the board after serving since February 2022. The board changes align with the upcoming annual shareholders meeting.
Aspira Women's Health (NASDAQ:AWH) ha annunciato cambiamenti significativi nel consiglio di amministrazione con la nomina di tre nuovi direttori: il Dr. Jeffrey Cohen, Cindy Hundorfean e Jack Fraser. Il Dr. Cohen porta con sé oltre 40 anni di esperienza urologica e in chirurgia robotica, mentre Hundorfean contribuisce con la sua esperienza nella leadership sanitaria come partner presso The CEO Advisory Network. Fraser aggiunge competenza finanziaria grazie ai suoi 25 anni di carriera presso Seamark Capital.
L'azienda ha anche stipulato un accordo di acquisto di azioni da 2,0 milioni di dollari con Triton Funds LP. I proventi sosterranno le attività commerciali in corso, il capitale circolante e le spese aziendali generali. Un obiettivo chiave rimane quello di stimolare la crescita delle vendite e completare il loro attuale studio clinico sull'endometriosi per il test del sangue ENDOInform™.
La Dr.ssa Celeste Fralick lascerà il consiglio dopo aver servito dal febbraio 2022. I cambiamenti nel consiglio sono in linea con l'imminente assemblea annuale degli azionisti.
Aspira Women's Health (NASDAQ:AWH) ha anunciado cambios significativos en su junta directiva con el nombramiento de tres nuevos directores: el Dr. Jeffrey Cohen, Cindy Hundorfean y Jack Fraser. El Dr. Cohen aporta más de 40 años de experiencia en urología y cirugía asistida por robot, mientras que Hundorfean contribuye con su experiencia en liderazgo en salud como socia en The CEO Advisory Network. Fraser añade experiencia financiera de su carrera de 25 años en Seamark Capital.
La compañía también ejecutó un acuerdo de compra de acciones de 2.0 millones de dólares con Triton Funds LP. Los ingresos apoyarán las actividades comerciales en curso, el capital de trabajo y los propósitos corporativos generales. Un enfoque clave sigue siendo impulsar el crecimiento de ventas y completar su actual estudio clínico de endometriosis para la prueba de sangre ENDOInform™.
La Dra. Celeste Fralick dejará la junta después de haber servido desde febrero de 2022. Los cambios en la junta están alineados con la próxima reunión anual de accionistas.
Aspira Women's Health (NASDAQ:AWH)는 세 명의 새로운 이사를 임명하며 이사회의 중요한 변화를 발표했습니다: Dr. Jeffrey Cohen, Cindy Hundorfean, Jack Fraser입니다. Cohen 박사는 40년 이상의 비뇨기과 전문 지식과 로봇 보조 수술 경험을 가지고 있으며, Hundorfean은 The CEO Advisory Network의 파트너로서 고위 의료 리더십 경험을 제공합니다. Fraser는 Seamark Capital에서 25년 동안의 경력을 통해 재무 전문성을 더합니다.
회사는 또한 Triton Funds LP와 200만 달러의 주식 구매 계약을 체결했습니다. 수익금은 지속적인 상업 활동, 운영 자본 및 일반 기업 목적을 지원합니다. 주요 초점은 판매 성장을 촉진하고 ENDOInform™ 혈액 검사를 위한 현재의 자궁내막증 임상 연구를 완료하는 것입니다.
Celeste Fralick 박사는 2022년 2월부터 이사로 재직한 후 이사회를 떠날 예정입니다. 이사회의 변화는 다가오는 연례 주주 총회와 일치합니다.
Aspira Women's Health (NASDAQ:AWH) a annoncé des changements significatifs au sein de son conseil d'administration avec la nomination de trois nouveaux directeurs : Dr. Jeffrey Cohen, Cindy Hundorfean et Jack Fraser. Dr. Cohen apporte plus de 40 ans d'expertise en urologie et d'expérience en chirurgie assistée par robot, tandis que Hundorfean contribue avec son expérience en leadership dans le secteur de la santé en tant que partenaire au sein de The CEO Advisory Network. Fraser ajoute son expertise financière grâce à ses 25 années passées chez Seamark Capital.
La société a également signé un accord d'achat d'actions de 2,0 millions de dollars avec Triton Funds LP. Les recettes soutiendront les activités commerciales en cours, le fonds de roulement et les objectifs généraux de l'entreprise. Un objectif clé reste de stimuler la croissance des ventes et de compléter leur étude clinique actuelle sur l'endométriose pour le test sanguin ENDOInform™.
Dr. Celeste Fralick quittera le conseil après avoir servi depuis février 2022. Les changements au sein du conseil sont en accord avec la prochaine assemblée annuelle des actionnaires.
Aspira Women's Health (NASDAQ:AWH) hat bedeutende Veränderungen im Vorstand angekündigt, mit der Ernennung von drei neuen Direktoren: Dr. Jeffrey Cohen, Cindy Hundorfean und Jack Fraser. Dr. Cohen bringt über 40 Jahre urologische Expertise und Erfahrung in der roboterassistierten Chirurgie mit, während Hundorfean als Partnerin im The CEO Advisory Network Erfahrung in der Führung im Gesundheitswesen beisteuert. Fraser ergänzt die finanzielle Expertise aus seiner 25-jährigen Tätigkeit bei Seamark Capital.
Das Unternehmen hat zudem eine Aktienkaufvereinbarung über 2,0 Millionen Dollar mit Triton Funds LP abgeschlossen. Die Erlöse werden die laufenden Geschäftstätigkeiten, das Betriebskapital und allgemeine Unternehmenszwecke unterstützen. Ein zentrales Ziel bleibt, das Umsatzwachstum voranzutreiben und die aktuelle klinische Studie zur Endometriose für den ENDOInform™ Bluttest abzuschließen.
Dr. Celeste Fralick wird den Vorstand verlassen, nachdem sie seit Februar 2022 gedient hat. Die Veränderungen im Vorstand stehen im Einklang mit der bevorstehenden jährlichen Hauptversammlung der Aktionäre.
- Strengthened board expertise with three new directors bringing healthcare, medical, and financial experience
- Secured $2.0 million in additional funding through equity purchase agreement
- Advancing development of ENDOInform™ blood test for endometriosis detection
- Loss of board member Dr. Celeste Fralick's data analytics expertise
- Potential shareholder dilution from new equity issuance
New Directors Bring Extensive Commercial Healthcare Relationships to Expand Business Development Opportunities.
AUSTIN, TX / ACCESS Newswire / April 8, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of three new Directors to its Board of Directors. These appointments were part of a planned Board change, aligned with the upcoming annual shareholders meeting. Each of the three new appointees brings extensive resumes, with the first two Directors, Dr. Jeffrey Cohen and Cindy Hundorfean, bringing decades of experience in executive roles within the health care and medical industries. Jack Fraser brings decades of financial and operational expertise to the Company's Board of Directors.
"We are pleased to welcome Dr. Cohen, Ms. Hundorfean, and Mr. Fraser to the Board of Directors," said Michael Buhle, Chief Executive Officer of Aspira Women's Health. "Each new director brings a diverse and critical expertise to the Board. This added knowledge and resources will be invaluable to the Company as we look to accelerate the pace of growth in our business and pursue our mission to bring much-needed changes to women's healthcare."
"The Board and the executive team would also like to extend our deepest gratitude to Dr. Celeste Fralick for her invaluable contributions as a member of our Board of Directors since February of 2022," stated Jannie Herchuk, Chair of the Board of Aspira Women's Health. "Her leadership, insight, and unwavering commitment have played a vital role in guiding the company through important milestones and shaping our strategic direction. Dr. Fralick's unique data analytics perspective and dedication have been instrumental in helping us navigate both opportunities and challenges, and we are truly grateful for the time, energy, and expertise you have generously shared."
With more than forty years as a practicing urologist, Dr. Cohen is an expert in robot-assisted surgery. Dr. Cohen has worked with the Allegheny Health Network since 1985, most recently as its Chief Physician Executive, Community Health and Innovation. He graduated in 1976 from Syracuse University with a Bachelor of Science in Biology and received his medical degree from SUNY - Upstate Medical Center in 1979. Dr. Cohen completed a residency in urology at Case Western Reserve University in 1984 and a fellowship in urology at The M.D. Anderson Cancer Center.
Ms. Hundorfean is a senior partner of The CEO Advisory Network and serves on the board of directors for several companies, including Avant-gard Health, Leadline, Inc. and Heuro Health. She has previously worked as Chief Living Health Development Officer for Highmark Health and as president and Chief Executive Officer for Allegheny Health Network. Ms. Hundorfean earned her Executive Master of Business Administration in Healthcare Administration from Case Western Reserve University.
Mr. Fraser has been a managing partner at the asset-management firm Seamark Capital for nearly 25 years. Mr. Fraser earned his Bachelor of Science in Business Administration from Bowling Green State University and his Masters in Business Administration in Finance from Ohio State University.
The Company is also announcing the execution of an equity purchase agreement with Triton Funds LP ("Triton"), for the issuance and sale of shares of the Company's common stock to be purchased by Triton for gross proceeds of up to
"We are also pleased to execute this key capital markets transaction. This financing transaction should play a critical role in supplementing our working capital for the foreseeable future as we execute our strategic growth initiatives. Our top operational priority is driving our sales growth, quickly followed by the completion of our current endometriosis clinical study, which is intended to validate our ENDOInform™ non-invasive blood test for the early detection endometriosis," concluded Mr. Buhle.
About Aspira Women's Health Inc.
Aspira Women's Health Inc. is dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases.
OvaWatch® and Ova1Plus® are offered to clinicians as OvaSuiteSM. Together, they provide the only comprehensive portfolio of blood tests to aid in the detection of ovarian cancer risk for the 1.2+ million American women diagnosed with an adnexal mass each year. OvaWatch provides a negative predictive value of
Our in-development test pipeline will expand our ovarian cancer portfolio and address the tremendous need for non-invasive diagnostics for endometriosis, a debilitating disease that impacts millions of women worldwide. In ovarian cancer, we intend to combine microRNA and protein biomarkers with patient data to further enhance the sensitivity and specificity of our current tests. In endometriosis, we have developed the first-ever non-invasive test designed to identify endometriomas, one of the most commonly occurring forms of severe endometriosis. Through our ongoing endometriosis development program, we are combining microRNA and protein biomarkers with patient data, with the intent of identifying all endometriosis independent of disease location or severity.
Forward-Looking Statements
This press release contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve a number of risks and uncertainties. Such forward-looking statements include statements regarding, among other things, the timing and completion of any products in the development pipeline and other statements that are predictive in nature, and whether the marketing of the OvaSuite portfolio will prove successful. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as "designed to," "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," and other words of similar meaning and the use of future dates. These and additional risks and uncertainties are described more fully in the Company's filings with the SEC, including those factors identified as "Risk Factors" in our most recent Annual Report on Form 10-K, for the fiscal year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Aspira presently does not know, or that Aspira currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Aspira's expectations, plans, or forecasts of future events and views as of the date of this press release. Subsequent events and developments may cause the Company's assessments to change. However, while Aspira may elect to update these forward-looking statements at some point in the future, Aspira expressly disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Aspira's assessments of any date after the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Investor Relations Contact:
Investors@aspirawh.com
SOURCE: Aspira Women's Health
View the original press release on ACCESS Newswire
FAQ
What is the value of Aspira's (AWH) new equity purchase agreement with Triton Funds?
Who are the three new directors appointed to Aspira's (AWH) board?
What is the primary use of funds from AWH's equity purchase agreement?
What is Aspira's (AWH) current clinical development focus?
